Mesoblast FY2026: Ryoncil Revenue Hits $115M, Phase 3 CLBP Trial Fully Enrolled
MESO sits 27% above its 52-week low of $12.66.
Summary
Mesoblast reported FY2026 revenue of $120.3M driven by $115.2M in Ryoncil sales, a 44% smaller net loss, and completion of treatment in its Phase 3 chronic low back pain trial.
Key Events · Earnings and Guidance · MESO
-
FY2026 Revenue Reaches $120.3M
Total revenue grew to $120.3M from $17.2M in FY2025, driven by $115.2M in net Ryoncil product sales after a 13.4% gross-to-net adjustment.
-
Gross Profit of $103.6M
Reported gross profit was $103.6M ($109.7M excluding amortization), versus $16.0M in the prior year, reflecting Ryoncil's strong commercial launch.
-
Net Loss Cut 44% to $57.5M
Net loss narrowed to $57.5M from $102.1M, with second-half loss of $17.3M — a 68% reduction versus the prior comparative period.
-
Cash Position of $103M
Period-end cash was $103M after net operating cash spend of $43.8M for the year, including only $13.4M in the second half.
Analysis · MESO · Life Sciences
Mesoblast delivered its first full-year commercial results with Ryoncil net revenue of $115.2M, up from $11.3M in the prior year, driving total revenue to $120.3M and gross profit to $103.6M. The company cut its net loss by 44% to $57.5M and reduced second-half operating cash burn to $13.4M, ending the year with $103M in cash. The filing also confirms completion of patient treatment in the pivotal Phase 3 chronic low back pain trial (350 patients) and commencement of the adult SR-aGvHD registration trial — two catalysts that position the company for label expansions into markets three times larger than the current pediatric indication.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $16.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $12.66 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.